AKT1 and Peritoneal Fibrosis: In summary, the mTORC1-specific blocker did not induce p-Akt up-regulation through negative feedback, and RAPA and BEZ235 both significantly down-regulated the mTOR pathway to inhibit the development and progression of peritoneal fibrosis.